Fundamental Analysis of FULCRUM THERAPEUTICS INC(NASDAQ:FULC) stock

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to FULC. FULC was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for FULC as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, FULC is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

FULC had negative earnings in the past year.

FULC had a negative operating cash flow in the past year.

In the past 5 years FULC always reported negative net income.

FULC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -6.88%, FULC is in the better half of the industry, outperforming 76.04% of the companies in the same industry.

FULC has a better Return On Equity (-7.39%) than 79.17% of its industry peers.

		Industry Rank	Sector Rank
ROA	-6.88%
ROE	-7.39%
ROIC	N/A

ROA(3y)-40.21%

ROA(5y)-51.33%

ROE(3y)-44.95%

ROE(5y)-62.45%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FULC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for FULC has been increased compared to 1 year ago.

FULC has more shares outstanding than it did 5 years ago.

There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

FULC has an Altman-Z score of 4.58. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.

FULC's Altman-Z score of 4.58 is fine compared to the rest of the industry. FULC outperforms 79.17% of its industry peers.

FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	4.58

ROIC/WACCN/A

WACC9.04%

2.3 Liquidity

A Current Ratio of 22.07 indicates that FULC has no problem at all paying its short term obligations.

FULC's Current ratio of 22.07 is amongst the best of the industry. FULC outperforms 93.75% of its industry peers.

A Quick Ratio of 22.07 indicates that FULC has no problem at all paying its short term obligations.

FULC has a better Quick ratio (22.07) than 93.75% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	22.07
Quick Ratio	22.07

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.56% over the past year.

The Revenue has grown by 2576.43% in the past year. This is a very strong growth!

The Revenue for FULC have been decreasing by -31.74% on average. This is quite bad

EPS 1Y (TTM)80.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%328.95%

Revenue 1Y (TTM)2576.43%

Revenue growth 3Y-31.74%

Revenue growth 5YN/A

Sales Q2Q%8990.91%

3.2 Future

The Earnings Per Share is expected to grow by 20.86% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 160.84% on average over the next years. This is a very strong growth

EPS Next Y82%

EPS Next 2Y10.14%

EPS Next 3Y5.51%

EPS Next 5Y20.86%

Revenue Next Year3365.58%

Revenue Next 2Y-41.42%

Revenue Next 3Y186.79%

Revenue Next 5Y160.85%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FULC. In the last year negative earnings were reported.

Also next year FULC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.14%

EPS Next 3Y5.51%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for FULC!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (11/4/2024, 8:10:42 PM)

After market: 3.26 0 (0%)

3.26

+0.05 (+1.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap203.42M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-6.88%
ROE	-7.39%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.28

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	22.07
Quick Ratio	22.07
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)80.56%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y82%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)2576.43%

Revenue growth 3Y-31.74%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

FULCRUM THERAPEUTICS INC (FULC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens